Pediatric Cancer News

Pediatric Cancer News

Higher Tisagenlecleucel Doses May Improve Outcomes in Youth With B-ALL

Publish Date August 10, 2022

Patients who received higher doses of tisagenlecleucel had improved overall survival, event-free survival, and relapse-free survival, with no increased toxicity.

Childhood Cancer Survivors Have Increased Risk of Inpatient Infections

Publish Date August 4, 2022

Childhood cancer survivors have an increased risk of inpatient infections 5 years or more after their cancer diagnosis.

Genetic Alterations ID’d in Many Pediatric Solid Tumors

Publish Date August 1, 2022

Researchers found clinically significant genetic variations in 86% of pediatric patients with extracranial solid tumors.

Durvalumab Plus Tremelimumab in Pediatric Patients With Advanced Cancers

Publish Date July 22, 2022

Researchers are conducting a phase 1/2 trial to evaluate durvalumab plus tremelimumab in pediatric patients with advanced cancers.

Avapritinib in Pediatric Patients With Solid Tumors, Glioma

Publish Date July 22, 2022

Researchers are conducting a phase 1/2 trial of avapritinib in pediatric patients who have relapsed or refractory solid tumors with mutations in KIT or PDGFRA or who have H3K27M-mutant glioma.

Alectinib in Patients With ALK Fusion-Positive Solid, CNS Tumors

Publish Date July 21, 2022

Researchers are conducting a phase 1/2 trial to test alectinib in pediatric patients with ALK fusion-positive solid tumors or CNS tumors.

Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy

Publish Date July 21, 2022

Researchers aim to determine if memantine can protect neurocognitive function in pediatric patients undergoing cranial radiotherapy to treat CNS tumors.

Race, Ethnicity Underreported in Early Phase Pediatric Cancer Trials

Publish Date July 20, 2022

Race and ethnicity were reported in less than 25% of the trials studied.

Health Insurance Status Linked to Disparities in Pediatric Cancer Diagnosis

Publish Date July 18, 2022

Disparities in cancer diagnoses among pediatric patients are partly a result of disparities in health insurance coverage, a study suggests.

Dinutuximab Plus GM-CSF Falls Short in Recurrent Osteosarcoma

Publish Date July 14, 2022

Dinutuximab plus GM-CSF produced a low disease control rate that did not meet a historical benchmark.

BMP4 Expression Levels May Predict Clinical Outcomes in Pediatric BCP-ALL

Publish Date July 14, 2022

BMP4 could be a therapeutic target in B-cell precursor acute lymphoblastic leukemia.

Carboplatin Deemed Acceptable Replacement for Actinomycin-D in Ewing Sarcoma

Publish Date July 12, 2022

There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.

1990 to 2019 Saw Decrease in Global Burden of Childhood Cancer

Publish Date July 1, 2022

The global burden of childhood cancer decreased from 1990 to 2019, and the greatest decrease was seen for leukemia.

Tisagenlecleucel Demonstrates Activity in Young Patients With R/R Non-Hodgkin Lymphoma

Publish Date June 29, 2022

Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.

Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors

Publish Date June 27, 2022

The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.

Repotrectinib Plus Chemotherapy in Patients With Relapsed/Refractory Solid Tumors

Publish Date June 21, 2022

Researchers are conducting a phase 1/2 trial to assess the safety and efficacy of combination repotrectinib, irinotecan, and temozolomide.

RRx-001 Plus Chemotherapy in Recurrent/Progressive Solid Tumors

Publish Date June 21, 2022

Researchers are conducting a phase 1 trial to assess the safety and efficacy of RRx-001 in combination with irinotecan and temozolomide.

Ibrutinib Plus Chemoimmunotherapy for Patients With Brain Cancer

Publish Date June 21, 2022

Researchers are conducting a phase 1 trial of ibrutinib plus indoximod, cyclophosphamide, and etoposide in patients with brain cancers.

Nivatrotamab in Patients With Relapsed/Refractory Solid Tumors

Publish Date June 21, 2022

Researchers will assess toxicity and pharmacokinetics in phase 1 and the antitumor activity of nivatrotamab in phase 2.

Upfront Radiotherapy May Benefit Medulloblastoma Patients With Li-Fraumeni Syndrome

Publish Date June 16, 2022

Patients with sonic hedgehog medulloblastoma and Li-Fraumeni syndrome have a “dismal” prognosis, according to researchers.